Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jan 18;66(1):e0143621.
doi: 10.1128/AAC.01436-21. Epub 2021 Oct 25.

Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects

Jeongjun Kim  1   2 , Jinho Choi  2 , Hwankyu Kang  2 , Jiye Ahn  2 , Jane Hutchings  2 , Christo van Niekerk  2 , Dongsik Park  2 , Jaeseung Kim  2 , Yeejin Jeon  2 , Kiyean Nam  2 , Soyoung Shin #  3 , Beom Soo Shin #  1
Affiliations
Randomized Controlled Trial

Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects

Jeongjun Kim et al. Antimicrob Agents Chemother. .

Abstract

Telacebec (Q203) is a potent drug candidate under clinical development for the treatment of drug-naïve and drug-resistant tuberculosis. The first-in-human randomized, placebo-controlled, double-blind, dose-escalation Phase 1A trial (Q203-TB-PI-US001) was conducted to evaluate the safety, tolerability, and pharmacokinetics of telacebec. A total of 56 normal, healthy, male and female subjects (42 active and 14 placebo) were enrolled in the study. The doses of telacebec were 10 mg (Cohort 1), 30 mg (Cohort 2), 50 mg (Cohort 3), 100 mg (Cohort 4), 200 mg (Cohort 5), 400 mg (Cohort 6), and 800 mg (Cohort 7) in a fasted state. Subjects participating in Cohort 4 were also enrolled in Cohort 8 to investigate the food effect on the pharmacokinetics of telacebec after a high-fat meal. In all subjects dosed with telacebec (10 to 800 mg), telacebec was well tolerated and did not lead to any significant or serious adverse events. Following a single oral administration of telacebec (10 to 800 mg), telacebec plasma concentration reached the maximal plasma concentration (Cmax) in average 2.0 to 3.5 h and showed multi-exponential decline thereafter. The area under the plasma concentration versus time curve (AUC) was approximately dose-proportional. A significant increase in plasma concentrations was observed in the fed condition compared with the fasted condition with the geometric mean ratio of 3.93 for Cmax. Moderate delay in Tmax (4.5 h) was also observed in the fed condition. These results, combined with the demonstrated activity against drug-sensitive and multidrug-resistant Mycobacterium tuberculosis, support further investigation of telacebec for the treatment of tuberculosis.

Keywords: Q203; pharmacokinetics; phase 1 trial; safety; telacebec; tolerability; tuberculosis.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Plasma concentration versus time profiles (A) for 48 h and (B) for 312 h after escalating single dose administration of telacebec from 10 mg to 800 mg in the fasted state. Data represent the mean ± SD (n = 6).
FIG 2
FIG 2
Systemic exposure represented by (A) Cmax, (B) AUClast, and (C) AUCinf versus dose of telacebec after single administration of telacebec in the fasted state. Data represent the mean ± SD (n = 6).
FIG 3
FIG 3
Plasma concentration versus time profiles (A) for 48 h and (B) for 312 h after administration of telacebec (100 mg) under fasted and fed conditions. Data represent the mean ± SD (n = 6).
See this image and copyright information in PMC

References

    1. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M, Zumla A. 2013. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 13:529–539. 10.1016/S1473-3099(13)70030-6. - DOI - PubMed
    1. Gunther G. 2014. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med (Lond) 14:279–285. 10.7861/clinmedicine.14-3-279. - DOI - PMC - PubMed
    1. World Health Organization. 2020. Global tuberculosis report 2020. WHO, Geneva, Switzerland.
    1. Visca D, Ong CWM, Tiberi S, Centis R, D'Ambrosio L, Chen B, Mueller J, Mueller P, Duarte R, Dalcolmo M, Sotgiu G, Migliori GB, Goletti D. 2021. Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology 27:151–165. 10.1016/j.pulmoe.2020.12.012. - DOI - PMC - PubMed
    1. Tadolini M, Codecasa LR, García-García J-M, Blanc F-X, Borisov S, Alffenaar J-W, Andréjak C, Bachez P, Bart P-A, Belilovski E, Cardoso-Landivar J, Centis R, D'Ambrosio L, Luiza De Souza-Galvão M, - Dominguez-Castellano A, Dourmane S, Fréchet Jachym M, Froissart A, Giacomet V, Goletti D, Grard S, Gualano G, Izadifar A, Le Du D, Marín Royo M, Mazza-Stalder J, Motta I, Ong CWM, Palmieri F, Rivière F, Rodrigo T, Silva DR, Sánchez-Montalvá A, Saporiti M, Scarpellini P, Schlemmer F, Spanevello A, Sumarokova E, Tabernero E, Tambyah PA, Tiberi S, Torre A, Visca D, Zabaleta Murguiondo M, Sotgiu G, Migliori GB. 2020. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J 56:2001398. 10.1183/13993003.01398-2020. - DOI - PMC - PubMed

Publication types